Rentosertib is an experimental lung disease drug developed by Insilico Medicine using AI. In a midstage study, it reduced biological age as measured by six aging clocks.

How was the drug tested?

The analysis included 42 patients with a chronic lung disease. Those given rentosertib showed reduced biological age, while placebo recipients saw little change on the same clocks.

What did the CEO say?

Alex Zhavoronkov said if your biological age is lower, you are likely to die later, but cautioned that results are early and long-term health effects on larger groups are unknown.

Large Language ModelsAI in HealthcareJapan Times TechSep 8, 2026Sep 8, 2026, 22:00 JST

AI Lung Drug Lowers Biological Age in Trial

Send on LINE

3 Key Points

What happened
In a midstage study, Insilico Medicine’s drug rentosertib reduced biological age, measured by six aging clocks, per an analysis in Nature Biotechnology. Placebo recipients saw little change.
Why it matters
The result suggests an AI-discovered lung drug may reverse aging markers, not just treat disease, a new potential use. The company is Hong Kong-listed.
What to watch
Whether the early results hold in larger, longer studies; the analysis included only 42 patients with chronic lung disease. CEO Alex Zhavoronkov cautioned the long-term health effects are unknown.

WHO IT HITSPatients with chronic lung disease and researchers studying aging could be affected, as the drug shows potential beyond its original purpose. Insilico Medicine and its investors also face the outcome of further trials.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Get these free every morning

Context & Analysis

The study marks a step for AI-discovered drugs, showing a lung disease treatment may also affect biological aging. Insilico Medicine, listed in Hong Kong, published the analysis in Nature Biotechnology.

Rentosertib reduced biological age across six aging clocks in a midstage trial with 42 patients. This suggests the drug might have broader uses, though the mechanism linking lung disease and aging is not detailed.

The results are early, and the long-term health effects are unknown. The company's CEO, Alex Zhavoronkov, cautions that larger studies are needed, so the potential for broader use hinges on further validation.

FAQ

What is rentosertib?: Rentosertib is an experimental lung disease drug developed by Insilico Medicine using AI. In a midstage study, it reduced biological age as measured by six aging clocks.
How was the drug tested?: The analysis included 42 patients with a chronic lung disease. Those given rentosertib showed reduced biological age, while placebo recipients saw little change on the same clocks.
What did the CEO say?: Alex Zhavoronkov said if your biological age is lower, you are likely to die later, but cautioned that results are early and long-term health effects on larger groups are unknown.

Japan Times TechRead Original Article

Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.